Skip to main content
Stonvex
Loading…
Home
Markets
Screener
Portfolio
Community
Stonvex publishes market data and research only.
Not investment advice. Not a registered investment advisor.
Read disclaimer
.
Stonvex
Search…
⌘K
Search…
⌘K
← Back to rankings
IKT
Live
Save
Overview
Financials
Filings
Earnings Calls
Short Interest
Ownership
Ratings
Peers
News
Log in
Get Started
Loading latest news…
52w low +21.1%
IKT
Inhibikase Therapeutics, Inc. Common Stock
☁️ News word cloud
Top words across the last 50 articles for this ticker.
nasdaq
therapeutics
gained
nyse
trading
after
inhibikase
results
rose
close
last
rating
high
period
announced
stocks
jumped
compared
parkinson
surged
StonvexStonvexStonvexStonvex